SARS-CoV-2 Variant Testing

摘要 EUA批准的新型SARS-CoV-2疫苗所提供的强大保护是COVID-19疫苗开发的一个重要里程碑。然而，变异体的出现引起了对目前批准的疫苗的保护效力的新的关注，这些疫苗失去了对一些变异体的中和效力。然而，新出现的数据表明，除了中和之外，在疫苗接种后早期出现的抗体功能，即使失去中和也会持续存在，可能有助于预防疾病。因此，在此，我们的目标是描述疫苗诱导的抗体的VOC特异性Fc效应子功能在疫苗平台上的宽度的演变。具体而言，我们的目标是分析亚类，同种型，Fc受体结合，补体沉积功能，细胞毒性，视蛋白吞噬活性，脱粒和粘液捕获接种后的天数相比，恢复期的个人。这些数据将与Novavax（和Medicago）和J& J的突破性感染病例进行比较。

Abstract The robust protection conferred by emerging EUA approved SARS-CoV-2 vaccines represents a critical milestone in COVID-19 vaccine development. However, the emergence of variants has inspired renewed concern related to the protective efficacy of currently approved vaccines, which lose neutralizing potency against some variants. However, emerging data suggest that antibody functions, beyond neutralization, that emerge early after vaccination and that persist even with a loss of neutralization, may contribute to protection from disease. Thus, here we aim to profile the evolution of the breadth of the VOC-specific Fc-effector functions of vaccine induced antibodies across vaccine platforms. Specifically, we aim to profile the subclass, isotypes, Fc-receptor binding, complement depositing function, cellular cytotoxicity, opsinophagocytic activity, degranulation, and mucus trapping days after vaccination compared to convalescent individuals. These data will be compared to breakthrough infection cases from Novavax (& Medicago) and J&J.